title: RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.
abstract: BACKGROUND
  The Gln allele of the Arg462Gln polymorphism in RNASEL results in a threefold decrease in enzymatic activity, a reported deficiency in apoptotic response, and has been associated with prostate cancer in some high-risk family studies. The relationship of this variant to sporadic prostate cancer remains uncertain.
  
  
  METHODS
  We conducted a nested case-control study of 1,317 prostate cancer cases and 1,842 controls from the screening arm of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Conditional logistic regression was used to evaluate the association between the RNASEL Arg462Gln polymorphism and prostate cancer.
  
  
  RESULTS
  No statistically significant association was observed between the Arg462Gln polymorphism and prostate cancer (compared to Arg/Arg, Gln/Arg: OR= 0.99 95% CI 0.84-1.16; Gln/Gln: OR= 0.95 95% CI 0.74-1.21), although slight non-significant differences in risk were observed among men with the Gln/Gln genotype by stage and grade.
  
  
  CONCLUSIONS
  These results suggest that the RNASEL Gln/Gln genotype does not play an important role in the etiology of prostate cancer in the general population.
authors.affiliation: Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. daughers@mail.nih.gov
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Daugherty
authors.forename: Richard B
authors.initials: RB
authors.lastname: Hayes
authors.forename: Meredith
authors.initials: M
authors.lastname: Yeager
authors.forename: Gerald L
authors.initials: GL
authors.lastname: Andriole
authors.forename: Nilanjan
authors.initials: N
authors.lastname: Chatterjee
authors.forename: Wen-Yi
authors.initials: WY
authors.lastname: Huang
authors.forename: William B
authors.initials: WB
authors.lastname: Isaacs
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Platz
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000235:genetics* / Q000517:prevention & control; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D016022:Case-Control Studies; D004247:DNA / Q000737:chemistry / Q000235:genetics; D004722:Endoribonucleases / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000517:prevention & control; D017422:Sequence Analysis, DNA
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004247:DNA; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease